CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
This article was originally published in The Pink Sheet Daily
Executive Summary
CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.